Mirxes Holding Company Limited (2629) has announced a voluntary memorandum of understanding with Apollo Health and Lifestyle Limited (AHLL), a wholly owned subsidiary of Apollo Hospitals Enterprise Limited. The agreement aims to explore a potential strategic collaboration focused on co-developing and commercializing advanced cancer early detection solutions in India and nearby regions.

Under the memorandum, a joint venture in India with an equity value of not less than US$50.00 million is anticipated, subject to agreed objectives and respective board approvals. Both parties plan to leverage Mirxes’ miRNA and multi-omics technologies—particularly GASTROClear and LUNGClear—alongside product pipelines for colorectal, liver, and breast cancers, as well as CADENCE multi-cancer tests. Apollo is expected to provide clinical expertise, a nationwide hospital network, and robust healthcare delivery capabilities.

Key proposed areas of collaboration include licensing intellectual property from Mirxes to the prospective joint venture for commercialization; working on additional preventive and precision healthcare diagnostics; and offering cancer early detection tests through Apollo’s extensive network of health screening facilities, pharmacies, and digital platforms. The memorandum extends until November 18, 2026, with no assurance that a final agreement will be reached.

Apollo, recognized for advanced care across South Asia and the Middle East, is noted for its leadership in preventive oncology and disease management. Mirxes anticipates that broader access to early cancer screening solutions can help address healthcare gaps through earlier clinical intervention. However, as stated in the announcement, the collaboration under the MOU may or may not proceed, and investors are advised to exercise caution when dealing in the shares of Mirxes.